Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in the 20-Valent Pneumococcal Conjugate Vaccine in the Adult Population in France
Clicks: 1
ID: 319653
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #191 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Streptococcus pneumoniae causes invasive pneumococcal disease and pneumonia. This study models the burden of adult pneumococcal disease in France. Over a 5-year period, approximately 630,000 cases and €3.1 billion of costs were attributable to pneumococcus, mostly non-invasive disease, with nearly 80% due to serotypes included in 20-valent pneumococcal conjugate vaccine.
| Reference Key |
openalex_W7167360905
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Euan Dawson, S. Fiévez, E. Blanc, Jeffrey Vietri, Mark Rozenbaum, Liêm Binh Luong Nguyen |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag381
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.